BR112023001195A2 - Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto - Google Patents
Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do compostoInfo
- Publication number
- BR112023001195A2 BR112023001195A2 BR112023001195A BR112023001195A BR112023001195A2 BR 112023001195 A2 BR112023001195 A2 BR 112023001195A2 BR 112023001195 A BR112023001195 A BR 112023001195A BR 112023001195 A BR112023001195 A BR 112023001195A BR 112023001195 A2 BR112023001195 A2 BR 112023001195A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- racemate
- tautomer
- stereoisomer
- isotopically labeled
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 17
- 238000000034 method Methods 0.000 title abstract 4
- 239000000651 prodrug Substances 0.000 title abstract 4
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 230000004913 activation Effects 0.000 title abstract 3
- 230000024203 complement activation Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title abstract 2
- 102000003712 Complement factor B Human genes 0.000 abstract 1
- 108090000056 Complement factor B Proteins 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
COMPOSTO OU RACEMATO, ESTEREOISÔMERO, TAUTÔMERO, COMPOSTO ISOTOPICAMENTE ROTULADO, SOLVATO, POLIMORFO, SAL FARMACEUTICAMENTE ACEITÁVEL OU COMPOSTO PRÓ-FÁRMACO DO MESMO, COMPOSTO, MÉTODO DE PREPARAÇÃO PARA COMPOSTO OU RACEMATO,ESTEREOISÔMERO, TAUTÔMERO, COMPOSTO ISOTOPICAMENTE ROTULADO, SOLVATO, POLIMORFO, SAL FARMACEUTICAMENTE ACEITÁVEL OU COMPOSTO DE PRÓ-FÁRMACO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA TRATAR UMA DOENÇA ASSOCIADA COM A ATIVAÇÃO DO CAMINHO ALTERNATIVO DE COMPLEMENTO, E, USO DO COMPOSTO. Um composto heterocíclico contendo piperidinila representado pela fórmula (I). O composto trata enfermidades e doenças relacionadas com a ativação do caminho alternativo de complemento pela inibição/regulagem de um Fator B de complemento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010790872 | 2020-08-07 | ||
PCT/CN2021/110859 WO2022028527A1 (zh) | 2020-08-07 | 2021-08-05 | 补体因子b抑制剂及其药物组合物、制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023001195A2 true BR112023001195A2 (pt) | 2023-02-28 |
Family
ID=80117021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023001195A BR112023001195A2 (pt) | 2020-08-07 | 2021-08-05 | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230286947A1 (pt) |
EP (2) | EP4282486A3 (pt) |
JP (2) | JP2023538844A (pt) |
KR (2) | KR20230049115A (pt) |
CN (1) | CN114057758A (pt) |
AU (2) | AU2021323300A1 (pt) |
BR (1) | BR112023001195A2 (pt) |
CA (1) | CA3188363A1 (pt) |
IL (2) | IL300432A (pt) |
MX (1) | MX2023001517A (pt) |
TW (3) | TW202344503A (pt) |
WO (1) | WO2022028527A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4273136A1 (en) * | 2020-12-30 | 2023-11-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing bridged heterocyclic compound, preparation method therefor, and medical use thereof |
WO2022218429A1 (zh) * | 2021-04-16 | 2022-10-20 | 正大天晴药业集团股份有限公司 | 一系列双环取代的芳香羧酸类化合物 |
EP4346812A2 (en) * | 2021-06-03 | 2024-04-10 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
AU2022329230A1 (en) * | 2021-08-18 | 2024-03-21 | Xizang Haisco Pharmaceutical Co., Ltd. | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine |
WO2023072197A1 (en) * | 2021-10-27 | 2023-05-04 | Hansoh Bio Llc | Piperidinyl indole derivatives, preparation methods and medicinal uses thereof |
WO2023139534A1 (en) * | 2022-01-24 | 2023-07-27 | Novartis Ag | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
TW202329939A (zh) * | 2022-01-26 | 2023-08-01 | 大陸商上海美悦生物科技發展有限公司 | 補體因子b抑制劑的鹽型、晶型及其製備方法和用途 |
TW202346279A (zh) * | 2022-04-01 | 2023-12-01 | 瑞士商諾華公司 | 補體因子b抑制劑及其用途 |
CN114805107B (zh) * | 2022-04-06 | 2024-03-26 | 哈尔滨工业大学(深圳) | 一种光催化实现的含氮杂环N-α位芳基化方法 |
WO2023237012A1 (zh) * | 2022-06-07 | 2023-12-14 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸类氘代化合物 |
WO2023237041A1 (zh) * | 2022-06-10 | 2023-12-14 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸酯类化合物 |
WO2023246677A1 (zh) * | 2022-06-20 | 2023-12-28 | 深圳信立泰药业股份有限公司 | 一种吲哚-苯基哌啶化合物及其制备方法与应用 |
WO2023246870A1 (zh) * | 2022-06-23 | 2023-12-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
WO2024002353A1 (zh) * | 2022-06-30 | 2024-01-04 | 江苏恒瑞医药股份有限公司 | 一种含氮桥杂环衍生物的可药用盐、晶型及其制备方法 |
WO2024017299A1 (zh) * | 2022-07-20 | 2024-01-25 | 正大天晴药业集团股份有限公司 | 一种桥杂环取代的苯酸衍生物或其盐的结晶及其制备方法 |
WO2024046277A1 (zh) * | 2022-08-29 | 2024-03-07 | 南京明德新药研发有限公司 | 一系列含氮桥杂环化合物及其制备方法 |
WO2024049977A1 (en) | 2022-08-31 | 2024-03-07 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
WO2024051849A1 (en) * | 2022-09-10 | 2024-03-14 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | 2-substituted piperidine derivatives, preparation methods and medicinal uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2014008040A0 (en) | 2012-05-04 | 2014-10-31 | Novartis Ag | Complement pathway modulators and uses thereof |
KR20150033652A (ko) | 2012-06-20 | 2015-04-01 | 노파르티스 아게 | 보체 경로 조절제 및 그의 용도 |
WO2014143638A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases |
JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
MY181251A (en) | 2013-09-13 | 2020-12-21 | Ionis Pharmaceuticals Inc | Modulators of complement factor b |
WO2015066241A1 (en) | 2013-10-30 | 2015-05-07 | Novartis Ag | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
CA3029262A1 (en) * | 2016-06-27 | 2018-01-04 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
KR102497487B1 (ko) * | 2017-08-31 | 2023-02-08 | 노파르티스 아게 | 피페리디닐-인돌 유도체의 신규 용도 |
-
2021
- 2021-08-05 KR KR1020237007883A patent/KR20230049115A/ko active Application Filing
- 2021-08-05 EP EP23201499.3A patent/EP4282486A3/en active Pending
- 2021-08-05 BR BR112023001195A patent/BR112023001195A2/pt unknown
- 2021-08-05 WO PCT/CN2021/110859 patent/WO2022028527A1/zh unknown
- 2021-08-05 EP EP21854197.7A patent/EP4194451A1/en active Pending
- 2021-08-05 CN CN202110898008.4A patent/CN114057758A/zh active Pending
- 2021-08-05 IL IL300432A patent/IL300432A/en unknown
- 2021-08-05 MX MX2023001517A patent/MX2023001517A/es unknown
- 2021-08-05 KR KR1020237039848A patent/KR20230161545A/ko active Application Filing
- 2021-08-05 AU AU2021323300A patent/AU2021323300A1/en active Pending
- 2021-08-05 JP JP2023508559A patent/JP2023538844A/ja active Pending
- 2021-08-05 US US18/040,962 patent/US20230286947A1/en active Pending
- 2021-08-05 IL IL308491A patent/IL308491A/en unknown
- 2021-08-05 CA CA3188363A patent/CA3188363A1/en active Pending
- 2021-08-06 TW TW112126793A patent/TW202344503A/zh unknown
- 2021-08-06 TW TW110129199A patent/TWI811756B/zh active
- 2021-08-06 TW TW112126792A patent/TW202344507A/zh unknown
-
2023
- 2023-11-17 JP JP2023195651A patent/JP2024023325A/ja active Pending
-
2024
- 2024-01-02 AU AU2024200019A patent/AU2024200019A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL300432A (en) | 2023-04-01 |
TW202344507A (zh) | 2023-11-16 |
CA3188363A1 (en) | 2022-02-10 |
CN114057758A (zh) | 2022-02-18 |
AU2021323300A1 (en) | 2023-04-06 |
EP4282486A2 (en) | 2023-11-29 |
EP4282486A3 (en) | 2024-03-06 |
EP4194451A1 (en) | 2023-06-14 |
TWI811756B (zh) | 2023-08-11 |
TW202344503A (zh) | 2023-11-16 |
US20230286947A1 (en) | 2023-09-14 |
TW202214653A (zh) | 2022-04-16 |
KR20230161545A (ko) | 2023-11-27 |
MX2023001517A (es) | 2023-03-06 |
IL308491A (en) | 2024-01-01 |
AU2024200019A1 (en) | 2024-01-25 |
WO2022028527A1 (zh) | 2022-02-10 |
KR20230049115A (ko) | 2023-04-12 |
JP2023538844A (ja) | 2023-09-12 |
JP2024023325A (ja) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023001195A2 (pt) | Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto | |
DOP2020000037A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
CO2021013030A2 (es) | Inhibidores de la proteína tirosina fosfatasa | |
MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
BR112022010383A2 (pt) | Compostos tricíclicos substituídos | |
BR112021024131A2 (pt) | Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo | |
BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
UY31027A1 (es) | Derivados de tetrahidroindol y tetrahidroindazol | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
BR112021022255A2 (pt) | Composto usado como inibidor de quinase e aplicação do mesmo | |
BR112021018169A2 (pt) | Composto para o controle de diabetes de felinos | |
ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
BR112022018515A2 (pt) | Terapia de combinação para leucemia mieloide aguda | |
BR112022009533A2 (pt) | Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica |